NOVADEL ANNOUNCES FILING OF NDA FOR THE ZENSANA (ONDANSETRON HCL) ORAL SPRAY

NovaDel Pharma today announced the submission of the New Drug Application (NDA) for Zensana (Ondansetron HCl) Oral Spray to the US Food and Drug Administration (FDA) by its partner Hana Biosciences.
Genetic Engineering News